Revenue
2020
2021
2022
2023
2024
2025
Starling Oncology, Inc. (STLN)
Price$5.93Cached quote
Net income
2020
2021
2022
2023
2024
2025
Free cash flow
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Revenue | $502.7M | $393.4M | $324.2M | $252.5M | $203.0M | $187.5M |
| Operating expenses | $538.8M | $453.5M | $401.3M | $334.4M | $248.9M | $195.7M |
| Operating income | −$36.1M | −$60.1M | −$77.0M | −$82.0M | −$45.9M | −$8.2M |
| Operating margin | −7.18% | −15.28% | −23.75% | −32.46% | −22.59% | −4.37% |
| EBITDA | −$29.1M | −$53.8M | −$71.1M | −$77.5M | −$42.5M | −$5.0M |
| EBITDA margin | −5.80% | −13.68% | −21.94% | −30.71% | −20.94% | −2.68% |
| Net income | −$60.6M | −$64.7M | −$83.1M | $152,000 | −$10.9M | −$14.3M |
| Net profit margin | −12.06% | −16.44% | −25.62% | 0.06% | −5.38% | −7.64% |
| Basic EPSper basic share | -$0.54 | -$0.71 | -$0.92 | $0.00 | -$0.16 | -$0.24 |
| Diluted EPSper diluted share | -$0.54 | -$0.71 | -$0.92 | -$0.21 | -$0.16 | -$0.24 |
Owners
Reported shareholders
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 23, 2026Form 4 | Chernett JoreyTenPercentOwner | BuyCommon Stock | 18.0K | $5.02 | $90.4K | 10.62M |
| Jun 8, 2026Form 4 · 10b5-1 | Podnos YaleChief Medical Officer | SellCommon Stock | 23.5K | $5.38 | $126.2K | 259.5K |
| Jun 4, 2026Form 4 | Chernett JoreyTenPercentOwner | BuyCommon Stock | 12.0K | $4.75 | $57.0K | 10.58M |
| May 20, 2026Form 4 | Chernett JoreyTenPercentOwner | BuyCommon Stock | 33.5K | $4.07 | $136.3K | 10.57M |
| May 19, 2026Form 4 | Chernett JoreyTenPercentOwner | BuyCommon Stock | 5.0K | $4.05 | $20.3K | 10.53M |